Clinical Observation on efficacy and safety of Telmisartan hydrochlorothiazide and Telmisartan in patients with Mild to Moderate Essential hypertension
Ma Wenjun,Yang Lirui,Zhang Huimin,Huang Jianfeng,Wu Haiying,Li zhanquan,Li Tianchang,Liu Xiaohui,Li Guangping,Jiang Hong,Wang Daowen,Hua Qi
DOI: https://doi.org/10.3969/j.issn.1671-6272.2012.04.005
2012-01-01
Abstract:Objective To evaluate the efficacy and safety of telmisartan+hydrochlorothiazide(T-H) and telmisartan monotherapy(T-m) in patients with mild to moderate essential hypertension.Methods This was a multicenter,randomized,double-blind,double-dummy,comparative,controlled trial.After a 2-week,single-blind,placebo run-in period,patients with mild to modertate hypertension were eligible to enter the 4-week,single-blind treatment with telmisartan monotherapy.Next,if DBP < 90mmHg,the patients will be excluded;if 90 ≤ DBP < 110 mmHg,the patients will enter the 8-week,double-blind,double-dummy therapy period and according to the randomized principle,they were divided into two groups.Study comparisons were between once-daily telmisartan+hydrochlorothiazide and telmisartan monotherapy.The primary endpoint was the decline of DBP from week 4 to week 12.Blood biochemical examinations,ECG,ABPM,etc were the observational parameters,too.Results(1) In total,300 patients(eight hospitals) were enrolled in and 213 patients had completed the study.One severe adverse event—myocardial infarction—ccurred in a patient,but it was considerd drug independent.(2) When unblinded,it revealed that there was a significant significance in the decline of DBP(A(12.66±10.76)mmHg,B(7.89±12.15)mmHg,P=0.0203).(3) At week 12,both groups had a sharply drop of BP,but T-H provided significantly greater reductions than T-m(SBP:P=0.0016;DBP:P=0.0186).The total efficacy rate was higher in T-H group(T-H:83.1%;T-m:67.2%,P<0.05),and the BP target achievement rate(T-H:71.8%,T-m:54.9%,P=0.0061),as well.The T/P ratio was>50% in both groups.(4) There was no significant difference between the two groups in the rate of total adverse events(T-H:21.8%,T-m:22.1%,P=0.9461) and drug-dependent adverse events(T-H:8.1;T-m:9.8%.P=0.6264).Conclusions T-H and T-m can both significantly and steadily reduce SBP and DBP and are very safe,well tolerated and accepted by patients with mild to moderate essential hypertension.T-H provides significantly greater BP lowering than T-m.